Related Experiment Video
Updated: Feb 8, 2026

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma
Published on: March 30, 2018
Economic burden of patients with diffuse large B-cell and follicular lymphoma treated in the USA
Vicki A Morrison1, Jill A Bell2, Laurie Hamilton3
1Hematology/Oncology & Infectious Disease, Hennepin County Medical Center, University of Minnesota, 701 Park Ave Ste 310, Minneapolis, MN 55415, USA.
Insights
The economic burden of treating diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) is significant, particularly in the initial year post-diagnosis. Costs and healthcare utilization decrease in the second year.
Area of Science:
- Hematology
- Oncology
- Health Economics
Background:
- Diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) are common B-cell malignancies.
- Understanding the economic impact of these diseases is crucial for healthcare planning and resource allocation.
Purpose of the Study:
- To evaluate the healthcare costs and utilization patterns associated with treated DLBCL and FL patients.
- To assess the economic burden in the initial period following diagnosis.
Main Methods:
- Retrospective analysis of adult patients with newly diagnosed DLBCL and FL.
- Data sourced from the Optum™ claims database between January 1, 2008, and October 31, 2015.
- Healthcare costs and utilization were tracked from diagnosis to the end of the follow-up period.
Main Results:
- The study identified 1267 DLBCL and 1595 FL patients.
- Mean monthly costs per patient were US$11,890 for DLBCL and US$10,460 for FL.
- Healthcare costs and utilization, including chemotherapy, inpatient admissions, and outpatient services, decreased from year 1 to year 2 post-diagnosis.
Conclusions:
- The economic burden of treated DLBCL and FL is substantial.
- The highest costs and utilization are observed in the first year after diagnosis.
Aim:
Evaluate healthcare costs and utilization of treated diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) patients.
Materials & Methods:
Adults with newly diagnosed DLBCL and FL between 1 January 2008 and 31 October 2015 were identified in the Optum™ claims database. Healthcare costs and utilization were assessed from diagnosis date until end of follow-up.
Results:
A total of 1267 DLBCL- and 1595 FL-treated patients were identified. Mean per-patient, per-month cost during follow-up was US$11,890 for DLBCL and US$10,460 for FL. Healthcare costs and utilization decreased from year 1 to 2 following diagnosis, due to a decrease in chemotherapy services, inpatient admissions and other outpatient services.
Conclusion:
The economic burden of treated DLBCL and FL is considerable, especially in the first year following diagnosis.
Related Concept Videos
Diffusion
Diffusion
Facilitated Diffusion
In this process, substrates such as organic compounds and ions interact with a transporter on one side, triggering conformational changes in proteins that enable...
Behavior of Gas Molecules: Molecular Diffusion, Mean Free Path, and Effusion
Protein Diffusion in the Membrane
Assessment of Diffusion and Perfusion
The Role of Diffusion in Respiration
Diffusion is the process by which molecules move from an area of higher concentration to an area of lower concentration. In the respiratory system, this...

